Table 2.

CEPAC^* model input parameters^† all time periods

Mean monthly CD4 count decrease (cells/μl), by HIV	CD4 > 500 cells/μl	CD4: 350 – 499 cells/μl	CD4: 200 – 299 cells/μl	CD4: 100 – 199 cells/μl	CD4: 50 – 99 cells/μl	CD4 < 50 cells/μl
RNA stratum, copies/mL
>100,000	9.54	7.94	6.34	4.66	3.30	1.37
30,000–100,000	9.54	7.94	6.34	4.66	3.30	1.37
10,000–30,000	6.85	5.70	4.55	3.34	2.37	0.98
3,000–10,000	5.87	4.88	3.90	2.87	2.03	0.84
500–3,000	4.77	3.97	3.17	2.33	1.65	0.69
20–500	2.45	2.03	1.63	1.19	0.85	0.35
0–20	2.45	2.03	1.63	1.19	0.85	0.35
Monthly risk of opportunistic infections (OIs), per 10,000	CD4 > 500 cells/μl	CD4: 350 – 499 cells/μl	CD4: 200 – 299 cells/μl	CD4: 100 – 199 cells/μl	CD4: 50 – 99 cells/μl	CD4 < 50 cells/μl
Pneumocystis pneumonia	4.0	8.0	16.0	61.8	110.0	83.6
Mycobacterium avium complex	1.0	3.0	3.0	12.0	26.0	46.9
Toxoplasmosis	0.5	1.0	2.0	3.0	10.0	7.0
Cytomegalovirus	1.0	3.0	7.0	13.0	31.0	81.7
Fungal infections	1.0	3.0	3.0	15.0	25.0	31.9
All other OIs	6.0	12.0	27.0	66.8	114.3	115.0
Monthly risk for acute OI-related death, among those with OI, %	Pneumocystis pneumonia	Mycobacterium avium complex	Toxoplasmosis	Cytomegalovirus	Fungal infections	All other OIs
	3.5	4.5	18.2	4.8	3.6	4.3
Efficacy of antiretroviral therapy	Viral suppression after 24 weeks, %		Monthly risk of late failure after initial viral suppression, %	On-treatment multiplier for OI incidence		On-treatment multiplier for chronic AIDS-related mortality
	86.0**		0.5**	1.0		1.0

^*CEPAC: Cost Effectiveness of Preventing AIDS Complications model; OIs: opportunistic infections

^†Parameter values for original CEPAC model before calibration

^**Values represent mean risk; individual’s risk of viral suppression and late failure depends on probability of treatment response